BlackRock reports 5.5% stake in MBX Biosciences
BlackRock, Inc. reports beneficial ownership of common stock of MBX Biosciences Inc. on a Schedule 13G. BlackRock reports beneficial ownership of 2,628,181 shares of MBX common stock, representing 5.5% of the outstanding class as of the reporting date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. reports beneficial ownership of common stock of MBX Biosciences Inc. on a Schedule 13G. BlackRock reports beneficial ownership of 2,628,181 shares of MBX common stock, representing 5.5% of the outstanding class as of the reporting date.
BlackRock has sole voting power over 2,583,923 shares and sole dispositive power over 2,628,181 shares, with no shared voting or dispositive power. Various underlying persons have rights to dividends or sale proceeds, but no individual person has an interest in more than five percent of MBX’s outstanding common shares.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole voting power financial
sole dispositive power financial
percent of class financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of MBX (MBX) common stock does BlackRock, Inc. report owning?
Why did BlackRock, Inc. file a Schedule 13G for MBX (MBX)?
Do any individual investors hold more than 5% of MBX (MBX) through BlackRock’s position?
AI-generated analysis. How Rhea-AI works. Not financial advice.